RxDoctor Payments Data

James Vaught, OD

Optometrist · Conway, SCNPI 1619224722

Payments from drug & device makers

$1,868in general payments, 2019–2025

Across 27 payments — averaging $69.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$443
  • Coopervision Inc.$374
  • LKC Technologies, Inc.$349
  • Optos, Inc.$200
  • Bausch & Lomb Americas Inc.$153
  • AbbVie$114
  • plus $234 from 4 others

What the payments were for

  • Food & beverage$1,868100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,868 in reported general payments places this provider in the 65th percentile of 653 optometrist providers in South Carolina.

See all optometrist providers in South Carolina

Medicare billing

Part B allowed, 2024
$82,038
Medicare patients
586
Services billed
1,052

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine45$51,208
LumiganBimatoprost21$15,168
VyzultaLatanoprostene Bunod12$4,666
SimbrinzaBrinzolamide/Brimonidine Tart17$3,493
Latanoprost280$2,799
CombiganBrimonidine Tartrate/Timolol14$2,722
Travoprost12$2,297
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat75$1,123
Prednisolone Acetate32$947
Brimonidine Tartrate44$829
Timolol Maleate55$752
ErythromycinErythromycin Base22$224
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha14$183
Doxycycline Monohydrate12$182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$114$69,09880 claims
Bausch & Lomb Americas Inc.Vyzulta$153$4,66612 claims
AlconSimbrinza$104$3,49317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 653 optometrist providers in South Carolina.

Other optometrist in Conway

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →